Combined intravitreal ranibizumab and photodynamic therapy for polypoidal choroidal vasculopathy

Retina

Volumn 32, Issue 7, 2012, Pages 1272-1279

  Saito, Masaaki ^a   Iida, Tomohiro ^a   Kano, Mariko ^a  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

age related macular degeneration; bevacizumab; indocyanine green angiography; optical coherence tomography; photodynamic therapy; polypoidal choroidal vasculopathy; ranibizumab; retinal pigment epithelial detachment; retinal pigment epithelium; vascular endothelial growth factor

Indexed keywords

RANIBIZUMAB; VERTEPORFIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; MALE; PHOTODYNAMIC THERAPY; POLYPOIDAL CHOROIDAL VASCULOPATHY; RETROSPECTIVE STUDY; TREATMENT DURATION; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CHOROID; CHOROID DISEASES; COMBINED MODALITY THERAPY; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; POLYPS; PORPHYRINS; RETINA; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84862883551     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e318236e624     Document Type: Article

References (39)

1. Yannuzzi LA, Sorenson J, Spaide RF, et al. Idiopathic poly-poidal. choroidal vasculopathy (IPCV). Retina 1990;10:1-8. (Pubitemid 20201879)
2. Spaide RF, Yannuzzi LA, Slakter JS, et al. Indocyanine green videoangiography of idiopathic polypoidal choroidal vasculop-athy. Retina 1995;15:100-110.
3. Yannuzzi LA, Ciardella A, Spaide RF, et al. The expanding clinical spectrum of idiopathic polypoidal choroidal vasculop-athy. Arch Ophthalmol 1997;115:478-485. (Pubitemid 27172703)
4. Imamura Y, Engelbert M, Iida T, et al. Polypoidal choroidal vasculopathy: a review. Surv Ophthalmol 2010;55:501-515.
5. Maruko I, Iida T, Saito M, et al. Clinical characteristics of exudative age-related macular degeneration in Japanese patients. Am J Ophthalmol 2007;144:15-22.
6. Lafaut BA, Leys AM, Snyers B, et al. Polypoidal choroidal vasculopathy in Caucasians. Graefes Arch Clin Exp Ophthal-mol 2000;238:752-759.
7. Kvanta A, Algvere PV, Berglin L, et al. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci 1996;37: 1929-1934. (Pubitemid 26324159)
8. Kliffen M, Sharma HS, Mooy CM, et al. Increased expression of angiogenic growth factors in age-related maculopathy. Br J Ophthalmol 1997;81:154-162. (Pubitemid 27092496)
9. Oh H, Takagi H, Takagi C. The potential angiogenic role of macrophages in the formation of choroidal neovascular membranes. Invest Ophthalmol Vis Sci 1999;40:1891-1898. (Pubitemid 29365148)
10. Rosenfeld PJ, Brown DM, Heier JS, et al. MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431. (Pubitemid 44511557)
11. Brown DM, Kaiser PK, Michels M, et al. ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355: 1432-1444. (Pubitemid 44511558)
12. Mitchell P, Korobelnik JF, Lanzetta P, et al. Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Br J Ophthalmol 2010;94:2-13.
13. Gomi F, Sawa M, Sakaguchi H, et al. Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy. Br J Oph-thalmol 2008;92:70-73.
14. Kokame GT, Yeung L, Lai JC. Continuous anti-VEGF treatment with ranibizumab for polypoidal choroidal vasculop-athy: an Interim 6-month report. Br J Ophthalmol 2010;94: 297-301.
15. Tano Y. Ophthalmic PDT Study Group: guidelines for PDT in Japan. Ophthalmology 2008;115:585-585.e6.
16. Gomi F, Ohji M, Sayanagi K, et al. One-year outcomes of photodynamic therapy in age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients. Ophthalmology 2008;115:141-146. (Pubitemid 350309415)
17. Saito M, Iida T, Nagayama D. Photodynamic therapy with verteporfin for age-related macular degeneration or polypoidal choroidal vasculopathy: comparison of the presence of serous retinal pigment epithelial detachment. Br J Ophthalmol 2008; 92:1642-1647.
18. Akaza E, Mori R, Yuzawa M. Long-term results of photody-namic therapy of polypoidal choroidal vasculopathy. Retina 2008;28:717-722. (Pubitemid 351655124)
19. Sato T, Kishi S, Matsumoto H, Mukai R. Combined photody-namic therapy with verteporfin and intravitreal bevacizumab for polypoidal choroidal vasculopathy. Am J Ophthalmol 2010;149:947-954.
20. Gomi F, Sawa M, Wakabayashi T, et al. Efficacy of intravitreal bevacizumab combined with photodynamic therapy for poly-poidal choroidal vasculopathy. Am J Ophthalmol 2010;150: 48-54.
21. Ruamviboonsuk P, Tadarati M, Vanichvaranont S, et al. Pho-todynamic therapy combined with ranibizumab for polypoidal choroidal vasculopathy: results of a 1-year preliminary study. Br J Ophthalmol 2010;94:1045-1051.
22. Maruko I, Iida T, Sugano Y, et al. Subfoveal retinal and cho-roidal thickness after verteporfin photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol 2011; 151:594-603.
23. Lee YH, Lee EK, Shin KS, et al. Intravitreal ranibizumab combined with verteporfin in photodynamic therapy for treating polypoidal choroidal vasculopathy. Retina 2011;31:1287-1293.
24. Rouvas AA, Papakostas TD, Ntouraki A, Lam DS. Photody-namic therapy, ranibizumab, and ranibizumab with photody-namic therapy for the treatment of polypoidal choroidal vasculopathy. Retina 2011;31:464-474.
25. Lai TY, Lee GK, Luk FO, Lam DS. Intravitreal ranibizumab with or without photodynamic therapy for the treatment of symptomatic polypoidal choroidal vasculopathy. Retina 2011;31:1581-1588.
26. Tano Y, Ohji M, Ishibashi T, et al. Re-treatment guideline of ranibizumab (genetical recombination) in the maintenance phase [in Japanese]. Nippon Ganka Gakkai Zasshi 2009;113: 1098-1103.
27. Saito M, Iida T, Kano M. Intravitreal ranibizumab for poly-poidal choroidal vasculopathy with recurrent or residual exudation. Retina 2011;31:1589-1597.
28. Treatment of Age-Related Macular Degeneration with Photo-dynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related mac-ular degeneration with verteporfin: one-year results of 2 randomized clinical trials\-TAP Report 1. Arch Ophthalmol 1999;117:1329-1345.
29. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 2009;148:43-58.
30. Kurashige Y, Otani A, Sasahara M, et al. Two-year results of photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol 2008;146:513-519.
31. Ishikawa K, Kondo M, Ito Y, et al. Correlation between focal macular electroretinograms and angiographic findings after photodynamic therapy. Invest Ophthalmol Vis Sci 2007;48: 2254-2259. (Pubitemid 351261303)
32. Hikichi T, Ohtsuka H, Higuchi M, et al. Improvement of an-giographic findings of polypoidal choroidal vasculopathy after intravitreal injection of ranibizumab monthly for 3 months. Am J Ophthalmol 2010;150:674-682.
33. Tatar O, Adam A, Shinoda K, et al. Expression of VEGF and PEDF in choroidal neovascular membranes following verte-porfin photodynamic therapy. Am J Ophthalmol 2006;142: 95-104.
34. Saito M, Shiragami C, Shiraga F, et al. Combined intravitreal bevacizumab and photodynamic therapy for retinal angioma-tous proliferation. Am J Ophthalmol 2008;146:935-941.
35. Saito M, Shiragami C, Shiraga F, et al. Comparison of intra-vitreal triamcinolone acetonide with photodynamic therapy and intravitreal bevacizumab with photodynamic therapy for retinal angiomatous proliferation. Am J Ophthalmol 2010; 149:472-481.
36. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intra-vitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007;143:566-583.
37. Kiss CG, Geitzenauer W, Simader C, et al. Evaluation of rani-bizumab-induced changes in high-resolution optical coherence tomographic retinal morphology and their impact on visual function. Invest Ophthalmol Vis Sci 2009;50:2376-2383.
38. Kohno R, Hata Y, Mochizuki Y, et al. Histopathology of neo-vascular tissue from eyes with proliferative diabetic retinopa-thy after intravitreal bevacizumab injection. Am J Ophthalmol 2010;150:223-229.
39. Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 2007; 114:2179-2182. (Pubitemid 350181137)